Stocks

Magazine articles on individual stocks, valuation, accounting standards, IPO's, brokerages, exchanges.

Old Articles: <Older 5431-5440 Newer>

The Motley Fool January 26, 2005 Rich Smith	Ford's Felicitous Fallacy The automaker predicts better profits in 2005.
The Motley Fool January 26, 2005 Rich Smith	J&J: Dialing for Dollars It pays to be big in a weak dollar world. Just ask Johnson & Johnson. Still, in the year to come, investors will want to keep one eye on J&J's operational performance, and the other on the U.S. Dollar's exchange rates against foreign currencies.
The Motley Fool January 26, 2005 Rex Moore	Juicing the Market's Returns You want to know exactly what actions you should take to finally get your investing house in order. The "Index Plus a Few" is a low-risk strategy with market-beating potential.
The Motley Fool January 26, 2005 Tim Beyers	The Rules of Rule Breaking The next ultimate growth stock is out there. Here is how to find it.
The Motley Fool January 26, 2005 Brian Gorman	Kraft's Problem Area International operations have to be high on the company's list as it seeks to improve its performance.
The Motley Fool January 26, 2005 Wherrett & Yelovich	A Giant Leap Toward IPO Their deal with Sharp of Japan is not only good for Nanosys but also should make Harris & Harris, one of the backers of Nanosys, a happy venture capital firm, since one of its investments continues to build a business before moving to that IPO.
The Motley Fool January 26, 2005 Stephen D. Simpson	Nice Quarter, Eh? Canadian National Railway hauls in the cash for the fourth quarter by hauling more commodities. Trading at just more than 16 times trailing earnings, CN looks like it's priced in line with its peers.
The Motley Fool January 26, 2005 Tom Gardner	Finding Lynch's 10-Baggers There's a method to finding tomorrow's home runs. This author has made it his mission to uncover the best underfollowed, under-appreciated companies before Wall Street gets on board.
The Motley Fool January 26, 2005 Stephen D. Simpson	The Pipeline to Biotech Success Looking at drug R&D is the best way to begin assessing biotech companies as possible investment opportunities.
The Motley Fool January 26, 2005 Marko Djuranovic	RedEnvelope's Merry Christmas If the online retailer can continue to develop unique gifts and attract site visitors, the profits should follow, perhaps as soon as fiscal year 2006.
<Older 5431-5440 Newer> Return to current articles.